Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Condition:   Prostate Cancer
Interventions:   Drug: Radium-223;   Radiation: stereotactic ablative radiotherapy (SABR)
Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 31, 2019 / by / in
Comments